JoyL Silva on the benefits of the integrated CDMO model with European Pharmaceutical Manufacturing
Pharma companies often need to access specialised manufacturing resources, facilities and capabilities to progress a drug from development through to commercial production. The outsourcing landscape is very fragmented and highly competitive, with a wide range of full service and niche contract development and manufacturing organisations (CDMOs) to choose from, as well as pure play and embedded CDMOs.
The embedded CDMO operates as a self-contained organisation within a larger biopharmaceutical company and is a unique option within the pharma and biopharma outsourcing space. Although it is not new, there is still a lack of understanding about it in the market. The European Pharmaceutical Manufacturer sat down with JoyL Silva, former General Manager of Pfizer CentreOne, to discuss the benefits an embedded CDMO model brings and how Pfizer CentreOne operates within one of the world’s premier biopharmaceutical companies.